Brief: Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103
17/12/2025 21:04
Dec 17 (Reuters) - Kalaris Therapeutics Inc KLRS.O: KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN TREATMENT-NAÏVE NEOVASCULAR AMD KALARIS THERAPEUTICS INC - TH103 GENERALLY WELL TOLERATED, SUPPORTING FURTHER DOSE ESCALATION KALARIS THERAPEUTICS INC - ACCELERATING ENROLLMENT IN PHASE 1B/2 STUDY; DATA EXPECTED 2H 2026 KALARIS THERAPEUTICS INC - TH103 SHOWED MEAN 10-LETTER GAIN IN VISUAL ACUITY AT MONTH 1 Source text: ID:nGNX6G773c Further company coverage: KLRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million